If NEDD9 overexpression is validated in future studies as an independent marker for a favorable outcome, it could be used for the development of risk-adapted post-remission chemotherapy protocols, to treat candidates with high probability of response among patients, included within the highly heterogeneous IR-AML subgroup. Here, NEDD9 is linked to acute myeloid leukemia.